Phase I, Multicenter, Open Label, Dose Escalation of (90)yttrium-Ibritumomab' Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+B-Cell Lymphoma Vaklavas, C., Meredith, R. F., Knox, S. J., Wiseman, G., Witzig, T. E., Micallef, I. N., Lobuglio, A. F., Forero, A. AMER SOC HEMATOLOGY. 2011: 716-717

View details for Web of Science ID 000299597102243